HIV-1 integrase inhibitor
544467-07-4
0.98%
2026-08-13
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Product Description
-
Seller Information
-
Description
ProductName HIV-1 integrase inhibitor Cat No CEI-1361 Description HIV-1 integrase inhibitor is an inhibitor of HIV-1 integrase used for anti-HIV. Product Overview HIV-1 integrase inhibitor is useful for anti-HIV, with IC50 value of 0.33 µM, which can target HIV-1 integrase and depress the activity in the treatment of HIV infection, AIDS, and other similar diseases characterized by integration of a retroviral genome into a host chromosome. HIV integrase is a 32 kDa protein produced from the C-terminal portion of the Pol gene product, an enzyme produced by HIV that enables its genetic material to be integrated into the DNA of the infected cell which are not to be confused with phage integrases and a key component in the retroviral pre-integration complex (PIC). HIV-1 integrase is composed of 3 structurally independent, functional domains: the N-terminal domain (NTD), catalytic core domain (CCD) and the C-terminal domain (CTD). The HIV-1 integration occurs through a multistep process that includes two catalytic reactions: 3'endonucleolytic processing of proviral DNA ends (termed 3'processing) and integration of 3'-processed viral DNA into cellular DNA (referred to as strand transfer). The human immunodeficiency virus (HIV) is the causative agent for the acquired immunodeficiency syndrome (AIDS), then HIV integrase is an attractive target for new anti-HIV drugs. The drug design of HIV-1 integrase inhibitor include integrase strand transfer inhibitors (INSTIs),inhibition of the LEDGF/p75-integrase interaction and integrase binding inhibitors, but strand transfer inhibition is the most intuitively obvious and readily pursued to date. Mg2+ and Mn2+ are critical cofactors in the integration phase, so removing these cofactors (e. g. through chelation) causes functional impairment of integrase. Competitive inhibitors compete directly with viral DNA for binding to integrase in order to inhibit 3‘-end processing. In doing this the inhibitors completely block the active site from binding to target DNA. INSTIs bind tightly and specifically to the IN that is associated with the ends of the DNA by chelating the divalent metal ions (Mg2+) which is coordinated by the catalytic triad, such as the DDE motif which is located in the CCD and is the active site of the enzyme. Development of a successful INSTI treatment was accomplished when raltegravir was discovered by Merck Sharp & Dohme Limited. S/GSK1349572 is an integrase inhibitor discovered by ViiV/Shinongi which was entering phase three in clinical trials in 2011.This new drug is promising and seems to be well tolerated and so far shows better results than both raltegravir and elvitegravir. CAS No 544467-07-4 Molecular Weight 247.21 Purity 0.98 Storage Store at -20°C Targets HIV Molecular Formula C11H9N3O4 Chemical Name (Z)-4-[3-(azidomethyl)phenyl]-4-hydroxy-2-oxobut-3-enoic acid Solubility Soluble in DMSO Shipping Conditions Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request category Inhibitors(c1514) cas_num 544467-07-4 Basic Info-
Product Name:
HIV-1 integrase inhibitor
Other Name:HIV-1 integrase inhibitor;(Z)-4-(3-(azidoMethyl)phenyl)-2-hydroxy-4-oxobut-2-enoic acid;4-[3-(Azidomethyl)phenyl]-2-hydroxy-4-oxo-2-butenoic acid
CAS No.:544467-07-4
Molecular Formula:C11H9N3O4
InChIKeys:ZIRLWIWYZCQZJW-UHFFFAOYSA-N
Molecular Weight:247.20686
Exact Mass:247.05930578 g/mol
Categories:
Characteristics-
PSA:
89 Ų
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Coenzymes,Inhibito,Enzymes,Zymogens,Substrates,Native Microorganism Creatine Amidinohydrolase
-
Location:
Shirley, New York 11967, USA
-
Payment Terms:
TT against copy of documents,D/P
-
Average lead Time:
15
-
Total Annual Revenue:
$1 million-$2.5 million
-
Year of Establishment:
2004
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product